Skip to main content

Test for FRα via IHC early to understand her treatment options at platinum resistance1,2

FRα=folate receptor alpha; IHC=immunohistochemistry.

 FRα Expression & Prevalence FRα Expression & Prevalence NCCN Guidelines MOD & MOA Why Testing Matters Why Testing Matters How to Test What Results Mean

Why FRα matters in advanced ovarian cancer

is a folate transport protein that is highly expressed in ovarian cancer.3*

~20,000

women are diagnosed with ovarian cancer
in the US each year and will need multiple therapy options1,4

women are diagnosed with
ovarian cancer
in the US each year and will need
multiple therapy options1,4

70%

are diagnosed at an advanced stage5

80%

will experience recurrence despite high CRR to surgery and 1L chemotherapy6

will experience recurrence despite high
CRR to surgery and 1L chemotherapy6

FRα is one of the most prevalent
biomarkers in ovarian cancer7-13

~1 in 3

patients with advanced
ovarian cancer

express FRα at a level that may make them candidates for ELAHERE monotherapy7,14

*Not to be confused with folate or folic acid.
1L=first-line; CRR=complete response rate; FRα=folate receptor alpha.

National Comprehensive Cancer Network® (NCCN®) recommendations for biomarker testing and subsequent treatment1,15

CLIA=Clinical Laboratory Improvement Amendments; FOLR1=folate receptor 1; FRα=folate receptor alpha.

The role of FRα in ovarian cancer16

ELAHERE IS DESIGNED TO TARGET FRα-EXPRESSING CELLS14

ELAHERE specifically targets FRα and delivers a cytotoxic DM4 payload14

ELAHERE is an antibody-drug conjugate (ADC) that binds to cell surface receptor FRα14,17-20

Graphic of ELAHERE attaching to outside of the cell

ELAHERE binds to FRα on the cell surface with high affinity
Graphic of ELAHERE attaching to outside of the cell

Upon binding, ELAHERE is internalized by the cell and delivers a cytotoxic molecule
Graphic of ELAHERE attaching to outside of the cell

This prompts intracellular release of DM4, a cytotoxic microtubule inhibitor, resulting in cell cycle arrest and apoptotic cell death
Graphic of ELAHERE attaching to outside of the cell

DM4 diffuses across the cell membrane and kills neighboring cells (bystander killing)*

*Via cell cycle arrest and apoptotic cell death.

The MOA of ELAHERE may affect cancer cells as well as healthy cells.21

FRα=folate receptor alpha; MOA=mechanism of action.

Need more information
about FRα (FOLR1) testing?

A representative can answer additional questions
you may have about testing for FRα with FOLR1 IHC.

REQUEST A REP

Take a look at
the clinical data

Explore the results of ELAHERE vs
standard chemotherapy.

VIEW THE DATA
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 28, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. James RL, Sisserson T, Cai Z, et al. Arch Pathol Lab Med. 2024;148(11):1226-1233. doi:10.5858/arpa.2023-0149-OA
  3. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Anal Biochem. 2005;338(2):284-293. doi:10.1016/j.ab.2004.12.026
  4. US Cancer Statistics Working Group. United States Cancer Statistics: Data Visualizations Tool. US Centers for Disease Control and Prevention. Published June 2025. Accessed October 28, 2025. https://gis.cdc.gov/Cancer/USCS/#/explore/incidence?cancer=52&datatype=1&dataset=
    standard&indicator=value&area=1&timeperiod=1&sexes=3&races=1&ages=23&tab=1&view=map&xaxis=sexes&shownational=1
  5. Surveillance, Epidemiology, and End Results Program. Recent trends in SEER age-adjusted incidence rates, 2000-2022. National Cancer Institute. Accessed October 28, 2025. https://seer.cancer.gov/statistics-network/explorer/application.html?site=40&data_type=1&graph_type=2
    &compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&stage=101&advopt_precision=1&advopt_show_ci=on&hdn_
    view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0
  6. Rose PG. Cancer Drug Resist. 2022;5(2):415-423. doi:10.20517/cdr.2022.01
  7. Matulonis UA, Lorusso D, Oaknin A, et al. J Clin Oncol. 2023;41(13):2436-2445. doi:10.1200/JCO.22.01900
  8. Kim Y-N, Chung YS, Park E, Lee ST, Lee J-Y. Sci Rep. 2024;14(1):7992. doi:10.1038/s41598-024-57515-y
  9. Harbin LM, Gallion HH, Allison DB, Kolesar JM. Diagnostics (Basel). 2022;12(4):842. doi:10.3390/diagnostics12040842
  10. Zhang S, Royer R, Li S, et al. Gynecol Oncol. 2011;121(2):353-357. doi:10.1016/j.ygyno.2011.01.020
  11. Atwal A, Snowsill T, Dandy MC, et al. Int J Cancer. 2022;151(9):1626-1639. doi:10.1002/ijc.34165
  12. Guan L, Li Z, Xie F, et al. J Exp Clin Cancer Res. 2020;39(1):53. doi:10.1186/s13046-020-01557-3
  13. Beck OG, Hardesty MM. Gynecol Oncol Rep. 2023;47:101187. doi:10.1016/j.gore.2023.101187
  14. ELAHERE. Package insert. AbbVie; 2025.
  15. VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. Package insert. Roche; 2022.
  16. Vergote IB, Marth C, Coleman RL. Cancer Metastasis Rev. 2015;34(1):41-52. doi:10.1007/s10555-014-9539-8
  17. Kovtun YV, Audette CA, Ye Y, et al. Cancer Res. 2006;66(6):3214-3221. doi:10.1158/0008-5472.CAN-05-3973
  18. Erickson HK, Park PU, Widdison WC, et al. Cancer Res. 2006;66(8):4426-4433. doi:10.1158/0008-5472.CAN-05-4489
  19. Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. J Control Release. 2018;284:49-56. doi:10.1016/j.jconrel.2018.06.016
  20. Miotti S, Canevari S, Ménard S, et al. Int J Cancer. 1987;39(3):297-303. doi:10.1002/ijc.2910390306
  21. Nguyen TD, Bordeau BM, Balthasar JP. Cancers (Basel). 2023;15(3):713. doi:10.3390/cancers15030713